The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Orally Disintegrating Tablet Market At The End Of The 2026–2030 Forecast Period?
The orally disintegrating tablet market size has experienced strong growth in recent years. Its value is anticipated to rise from $16.2 billion in 2025 to $17.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. During the historical period, this growth was impacted by factors including limited awareness of orally disintegrating tablets, the dominance of conventional tablets, low targeting of pediatric and geriatric populations, reliance on hospital pharmacy channels, and the slow adoption of specialty drug formulations.
The orally disintegrating tablet market size is projected to experience robust growth in the upcoming years. It is forecasted to reach $24.43 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.5%. The expansion during the forecast period is attributable to technological advancements in ODT formulation, a rising patient inclination for convenience and adherence, the proliferation of online and retail pharmacy networks, an increasing incidence of CNS and gastrointestinal disorders, and expanding research and development in anti-psychotics and anti-epileptics. Key trends observed in the forecast period encompass a surging demand for easily ingestible and patient-friendly dosage forms, an broadened focus on pediatric and geriatric patient demographics, the development of hospital and retail pharmacy distribution channels, an increased emphasis on rapid-onset therapeutics, and the growing adoption of specialty drug classes in ODT formulations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp
Which Market Drivers Are Supporting The Expansion Of The Orally Disintegrating Tablet Market?
The rising occurrence of neurological disorders is anticipated to stimulate the expansion of the orally disintegrating tablet market. These conditions are medical issues impacting the nervous system, including the brain and peripheral nerves, thereby disrupting its regular functions. The escalating prevalence of neurological disorders is primarily linked to increased longevity, as illnesses like Alzheimer’s and Parkinson’s become more prevalent with advancing age, contributing to a general rise in cases. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker medication delivery, especially for individuals facing difficulties with swallowing (dysphagia) or cognitive impairments, leading to better treatment compliance, timely dosing, and enhanced therapeutic efficacy. For example, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicated that in 2023, approximately 6.7 million Americans aged 65 and older are currently living with Alzheimer’s dementia, with forecasts suggesting this number will climb to 13.8 million by 2060. Consequently, the growing incidence of neurological disorders is a key factor boosting the orally disintegrating tablet market.
What Segment Types Make Up The Orally Disintegrating Tablet Market?
The orally disintegrating tablet market covered in this report is segmented –
1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes
Which Market Trends Are Creating New Opportunities In The Orally Disintegrating Tablet Market?
Companies with significant presence in the orally disintegrating tablet market are prioritizing novel drug formulation techniques, including patient-centric drug delivery systems, to boost patient compliance with treatments and achieve better health results. This type of system focuses on creating and providing medicines that are simpler and more pleasant for patients to consume, thereby enhancing their overall experience and consistency in taking medication. For example, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada in May 2025, presenting a new therapeutic choice for individuals with treatment-resistant schizophrenia. The product boasts several distinct features, marking it as a valuable advancement in the management of treatment-resistant schizophrenia within Canada. As the initial clozapine orally disintegrating tablet (ODT) to be released in the nation, it offers an accessible format that rapidly dissolves in the mouth without requiring water, which assists patients who struggle with swallowing or maintaining adherence. Available in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), the medication enables adaptable and precise dose adjustments according to specific patient requirements. By utilizing clozapine, recognized as the sole approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation ensures compliance with established treatment guidelines.
Who Are The Key Players Driving Competition In The Orally Disintegrating Tablet Market?
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.
Read the full orally disintegrating tablet market report here:
https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report
How Is The Orally Disintegrating Tablet Market Distributed Across Key Geographic Regions?
North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Orally Disintegrating Tablet Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp
Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company
Tablets Market Report 2026
https://www.thebusinessresearchcompany.com/report/tablets-global-market-report
Effervescent Tablet Market Report 2026
https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model